(Q45090368)

English

Prediction of breakthrough hepatitis due to lamivudine-resistant hepatitis B virus by a sensitive semiquantitative assay using peptide nucleic acids

scientific article published on 22 May 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Prediction of breakthrough hepatitis due to lamivudine-resistant hepatitis B virus by a sensitive semiquantitative assay using peptide nucleic acids (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Hepatitis B virus

1 reference

based on heuristic

inferred from title

peptide nucleic acid

1 reference

based on heuristic

inferred from title

author name string

Kojiro Mori

1

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Masahito Minami

2

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Toshihiko Kirishima

3

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Koji Kunimoto

4

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Mika Okita

5

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Mika Nakayama

6

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Akiko Makiyama

7

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Junko Yamaoka

8

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Tomoki Nakajima

9

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Kohichiroh Yasui

10

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Yoshito Itoh

11

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Takeshi Okanoue

12

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

publication date

22 May 2006

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

49

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

274-280

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Management of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1159%2F000093457

21 January 2018

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1159%2F000093457

21 January 2018

Histological outcome during long-term lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1159%2F000093457

21 January 2018

Viral breakthrough during lamivudine therapy for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1159%2F000093457

21 January 2018

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1159%2F000093457

21 January 2018

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1159%2F000093457

21 January 2018

Management of the patient with hepatitis B virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1159%2F000093457

21 January 2018

Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment

1 reference

https://api.crossref.org/works/10.1159%2F000093457

21 January 2018

Lamivudine therapy for Japanese patients with cirrhosis B.

1 reference

https://api.crossref.org/works/10.1159%2F000093457

21 January 2018

Long-term therapy of chronic hepatitis B with lamivudine.

1 reference

https://api.crossref.org/works/10.1159%2F000093457

21 January 2018

Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea

1 reference

https://api.crossref.org/works/10.1159%2F000093457

21 January 2018

Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers

1 reference

https://api.crossref.org/works/10.1159%2F000093457

21 January 2018

Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR.

1 reference

https://api.crossref.org/works/10.1159%2F000093457

21 January 2018

Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation

1 reference

https://api.crossref.org/works/10.1159%2F000093457

21 January 2018

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1159%2F000093457

21 January 2018

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1159%2F000093457

21 January 2018

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1159%2F000093457

21 January 2018

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

1 reference

https://api.crossref.org/works/10.1159%2F000093457

21 January 2018

Antivirals for the treatment of chronic hepatitis B: current and future options

1 reference

https://api.crossref.org/works/10.1159%2F000093457

21 January 2018

Identifiers

10.1159/000093457

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45090368&oldid=2065537298"